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Abstract
Aims: MICU1 encodes the gatekeeper of the mitochondrial Ca2+ uniporter, MICU1 and 
biallelic loss-of-function mutations cause a complex, neuromuscular disorder in children. 
Although the role of the protein is well understood, the precise molecular pathophysiol-
ogy leading to this neuropaediatric phenotype has not been fully elucidated. Here we 
aimed to obtain novel insights into MICU1 pathophysiology.
Methods: Molecular genetic studies along with proteomic profiling, electron-, light- and 
Coherent anti-Stokes Raman scattering microscopy and immuno-based studies of protein 
abundances and Ca2+ transport studies were employed to examine the pathophysiology 
of MICU1 deficiency in humans.
Results: We describe two patients carrying MICU1 mutations, two nonsense (c.52C>T; 
p.(Arg18*) and c.553C>T; p.(Arg185*)) and an intragenic exon 2-deletion presenting with 
ataxia, developmental delay and early onset myopathy, clinodactyly, attention deficits, 
insomnia and impaired cognitive pain perception. Muscle biopsies revealed signs of dys-
trophy and neurogenic atrophy, severe mitochondrial perturbations, altered Golgi struc-
ture, vacuoles and altered lipid homeostasis. Comparative mitochondrial Ca2+ transport 
and proteomic studies on lymphoblastoid cells revealed that the [Ca2+] threshold and the 
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INTRODUC TION
Mitochondrial disorders are genetically heterogeneous and normally 
manifest as multisystem diseases with very heterogeneous clini-
cal presentations based on the underlying molecular defect. Many 
syndromes caused by mutations affecting mitochondrial proteins 
are associated with a vulnerability of skeletal muscle, in addition to 
the nervous and ocular system. Mitochondrial diseases associated 
with myopathies are progressive disorders that produce significant 
disabilities and may cause premature death. However, within the 
clinical spectrum of multisystem mitochondrial diseases, the muscu-
lar phenotype may be outweighed by other clinical aspects such as 
neurodegeneration [1].
The mitochondrial Ca2+ uptake protein 1 (MICU1), encoded by 
the MICU1 gene is the primary Ca2+-sensing regulator of the pore of 
the mitochondrial Ca2+ uniporter formed by the mitochondrial cal-
cium uniporter protein (MCU) and Essential MCU regulator (EMRE) 
[2-4]. Loss-of-function mutations in the MICU1 gene cause an early 
onset multisystem disease characterised by proximal myopathy, 
learning difficulties and a progressive extrapyramidal movement dis-
order (OMIM #615673) [5]. MICU1(−/−) mice either die at birth, likely 
because of impaired neuronal respiratory control,[6] or are viable 
but manifest marked ataxia and muscle weakness [7]. At the cellular 
level, mitochondrial Ca2+ overload, resulting in altered mitochon-
drial morphology, reduced ATP-level and increased vulnerability to 
stress-induced cell death were documented [6,7]. In vitro studies of 
the functional consequences of MICU1 mutations in patient-derived 
fibroblasts showed mitochondrial fragmentation related to altered 
Ca2+-induced phosphorylation of DRP1 that initiates fission [8] 
and influences both cell survival and apoptosis. Thus, it has been 
assumed that MICU1 serves as a signal-noise discriminator in mito-
chondrial Ca2+ signalling that controls oxidative phosphorylation [9], 
a process of importance in tissues with dynamic energetic demands 
such as brain and skeletal muscle.
Although altered cellular Ca2+ homeostasis may impact on proper 
protein function and abundance, as well as on lipid homeostasis, the 
overall cellular protein and lipid composition in human MICU1-deficient 
cells or tissues has not been studied yet. Thus, we aimed to explore 
the biochemical consequences of MICU1 deficiency in patient-derived 
cells and muscle tissue. We report two patients with biallelic MICU1 
mutations. In a patient-derived lymphoblastoid cell line, the lack of 
MICU1 protein and MICU1-deficient mitochondrial Ca2+ transport 
phenotype were validated. Label-free proteomic profiling was carried 
out and findings obtained in cells correlated with the morphological 
and biochemical perturbations detected by subsequent studies includ-
ing light, electron and Coherent anti-Stokes Raman scattering (CARS) 
microscopy on the patient-derived muscle biopsies. Our study provides 
insights into myopathological and biochemical effects downstream of 
perturbed cellular Ca2+ homeostasis including an impact on Spectrin 
abundance and distribution as well as on lipid accumulation.
MATERIAL S AND METHODS
Molecular genetics
Blood genomic DNA from index patient 1 was subjected to whole 
genome sequencing by deCODE Genetics (Iceland) using the TruSeq 
PCR-free library preparation kits from Illumina. Sequencing librar-
ies were clustered to the surface of paired-end (PE) HiSeq X version 
2.5 flowcells, using the Illumina cBot™ instrument. Each library was 
hybridised to a single lane on a flowcell, yielding in general >30X se-
quence coverage. Real-time analysis involved conversion of image data 
to base calling. Alignment to the human reference sequence (hg19) 
and variant calling were carried out using Burrows–Wheeler Aligner 
(BWA; http://bio-bwa.sourc eforge.net/) and Genome Analysis ToolKit 
(GATK; https://softw are.broad insti tute.org/gatk/); variant call set was 
uploaded onto a proprietary genomics analysis platform (https://www.
wuxun extco de.com). We sought recessive variants (i.e. homozygous 
and compound heterozygous) that were rare in the control population 
(MAF ≤1% http://exac.broad insti tute.org/) and had an impact on the 
protein structure (moderate to high Ensembl Variant Effect Predictor 
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cooperative activation of mitochondrial Ca2+ uptake were lost in MICU1-deficient cells 
and that 39 proteins were altered in abundance. Several of those proteins are linked to 
mitochondrial dysfunction and/or perturbed Ca2+ homeostasis, also impacting on regu-
lar cytoskeleton (affecting Spectrin) and Golgi architecture, as well as cellular survival 
mechanisms.
Conclusions: Our findings (i) link dysregulation of mitochondrial Ca2+ uptake with muscle 
pathology (including perturbed lipid homeostasis and ER–Golgi morphology), (ii) support 
the concept of a functional interplay of ER–Golgi and mitochondria in lipid homeostasis 
and (iii) reveal the vulnerability of the cellular proteome as part of the MICU1-related 
pathophysiology.
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mitochondrial myopathy
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(VEP)). Sanger sequencing was used to confirm the identified MICU1 
variant and segregate it in the available family members.
A custom-designed Illumina Enrichment Kit was used to capture 
the genes under investigation in index patient 2. The generated library 
was sequenced on a MiSeq sequencer (Illumina). The generation of the 
analysed ‘bam’ or ‘FastQ’ files was carried out with the MiSeqReporter 
Software (v.2.6.2, Illumina, reference genome: hg19). Generated raw 
data were analysed using the SeqNext module of the SeqPatient soft-
ware (JSI, v.4.3.0-B503). Approximately 99% of the target regions of 
interest (ROI) were covered with a coverage of >30X.
Uniparental disomy for chromosome 10 (upd [10]) was excluded 
in index patient 2 by microsatellite analysis of highly polymorphic 
markers located on chromosome 10. A list of markers used may be 
provided upon request.
Analysis of copy numbers of exons encoding MICU1
Copy number variants of exons 1, 2 and 3, covering the presumed re-
arrangement of the MICU1 gene (NM_006077), were analysed in the 
DNA of patient 2 and his parents using qPCR. The respective qPCR 
primer sequences and conditions are available upon request. For the 
detection of larger genomic imbalances, the CytoScan® HD Array 
(Affymetrix, Santa Clara/CA, USA) was applied. Only CNVs >50 kb 
with a mean marker distance of <5 kb were considered.
Generation of a lymphoblastoid cell line
Lymphoblastoid cell lines were generated from peripheral blood 
samples derived from the index patient and the healthy sibling as 
described previously.[10]
Measurements of mitochondrial Ca2+ uptake in 
permeabilised lymphoblasts
Fluorometric measurements of cytosolic [Ca2+]c were performed as 
previously described [2]. Briefly, saponin-permeabilised lymphoblasts 
(2.4 mg) were resuspended in 1.5 mL of intracellular medium contain-
ing 120 mM KCl, 10 mM NaCl, 1 mM KH2PO4, 20 mM Tris-HEPES 
at pH 7.2 and supplemented with proteases inhibitors (leupeptin, 
antipain, pepstatin, 1 mg/ml each), 2 mM MgATP, 2 µM thapsigar-
gin (Enzo) and maintained in a stirred thermostated cuvette at 35 °C. 
Assays were performed in presence of 20 µM CGP-37157 (Enzo) and 
1 mM succinate using a multiwavelength-excitation dual-wavelength-
emission fluorimeter (DeltaRAM, PTI). The extramitochondrial Ca2+ 
concentration [Ca2+]c was assessed using the ratiometric Ca
2+ probe 
Fura2-FA (1.5 µM, Teflabs) or Fura-loAff (formerly Fura-FF) (1 µM, 
Teflabs). Fura fluorescence was recorded simultaneously using 340–
380 nm excitation and 500 nm emission. Calibration of the Fura signal 
was carried out at the end of each measurement, adding 1 mM CaCl2, 
followed by 10 mM EGTA/Tris, pH 8.5.
Immunoblotting of MICU1 and EMRE in 
lymphoblastoid cells
Western blotting of the permeabilised lymphoblast cells was carried 
out as described before [11].
Proteomic profiling
As proteomic profiling is a powerful tool to obtain unbiased insights 
into pathophysiological processes, label-free protein quantification 
utilising liquid chromatography coupled to tandem mass spectrom-
etry has been carried out on lymphoblastoid cells derived from one 
MICU1 patient and his healthy sibling (as control). For further details 
see Data S1.
Light, fluorescence and electron microscopy of 
patient-derived muscle biopsy
Seven-micrometre-thick sections were cut from cryopreserved muscle 
biopsy tissue. These sections were used for H&E staining and for en-
zyme histochemistry (NADH, ATPase, COX-SDH) as well as for immu-
nofluorescence (IF). Fluorescence studies were carried out as described 
previously [12]. Light and electron microscopic investigations of the 
patient-derived muscle biopsy were carried out as described previously 
[12,13]. Further immunological studies were performed on 7-µm-thick 
sections cut from muscle biopsy tissue fixed in formalin and embed-
ded in paraffin. Primary antibodies used are as follows: MICU1 (Abcam; 
dilution 1:100), POC1A (Sigma; dilution 1:100), STX5 (Thermo Fisher; 
dilution 1:100), GRP94 (Genetex; dilution 1:100), BiP (Genetex; dilution 
1:100), CALR (Genetex, dilution 1:100), BSCL2 (Cell Signalling; dilution 
1:100), LC-3 (Abcam; dilution 1:100), LAMP1 (Genetex; dilution 1:100), 
CASP1 (Santa Cruz; dilution 1:100), CytC (Santa Cruz; dilution 1:100), 
ACTN3 (Genetex; dilution 1:100) and ITGB4 (Millipore; dilution 1:100). 
Peroxidase-labelled secondary goat anti-rabbit and goat anti-mouse im-
munoglobulin antiserum (1:200, DCS, Hamburg, Germany) and diamin-
obenzidine (DAKO, USA) were used to detect antibody binding. Cellular 
structures were counter-stained with haematoxylin.
Coherent anti-Stokes Raman scattering and Second 
Harmonic Generation spectroscopy, non-linear 
unmixing and statistical evaluation of muscle 
fibre calibres
CARS and second harmonic generation (SHG) measurements were 
performed on a modified Leica TCS SP8 CARS with an APE pico-
Emerald laser system. Five-micrometre-thick sections were cut from 
FFPE tissue blocks and thoroughly deparaffinated. No further sam-
ple preparation was applied.
Non-linear unmixing of CARS data was performed as described 
previously [14] and the statistical evaluation was done on the basis 
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of the CARS images (69 CARS measurements and 3380 muscle fi-
bres in total).
For further details see Data S1.
Immunoblot studies on whole muscle protein extracts
SDS-PAGE and subsequent western blot studies on whole protein 
extracts from patient-derived muscle biopsies have been carried out 
as described previously [15]. Primary antibodies against β-Spectrin 
(Novo Castra/Leica; # NCL-SPEC1; dilution 1:500), Tubulin (Sigma, 
# T5168; dilution 1:1000), Myotilin (Novo Castra/Leica; # NCL-
MYOTILIN; dilution 1:10000), Dystrophin (Novo Castra/Leica; # 
NCL-DYS3; dilution 1:1000), Desmin (Novo Castra/Leica; # NCL-
DES-DERII; dilution 1:1000), β-Dystroglycan (Novo Castra/Leica; 
# NCL-b-DG; dilution 1:1000) and α-, β- and γ-Sarcoglycan (Novo 
Castra/Leica; # NCL-a-SARC/ NCL-b-SARC/ NCL-g-SARC; respec-
tive dilutions 1:1000) have been used.
F I G U R E  1  Clinical and genetic data of the MICU1 patients. (A) Family pedigree of index patient 1 showing the occurrence of five 
miscarriages. (B) Presentation of musculature in both index patients: loss of muscle mass in index patient 1 at the age of 36 months (B1). 
Pseudo-hypertrophy of calf muscles and tiptoes as preferred positioning of the legs in index patient 2 at the age of 32 months (B2). (C & 
D) Results of next generation sequencing (NGS) studies in both index patients: (C) genome sequencing studies in index case 1 identified 
a homozygous chr10: 74268012G>A change in the MICU1 gene (upper left panel). This mutation is absent in the DNA sample of a control 
sample (lower left panel). Sanger sequencing-based segregation studies revealed heterozygosity for the mutation in both consanguineous 
parents and confirmed the homozygous presence in the DNA sample of index patient 1 (black arrows in right panel). (D) Results of NGS-
based studies of exons and exon–intron boundaries revealed homozygosity for a sequence variant in exon 2 of the MICU1 gene (chr10: 
74268012; c.52C>T, p.(Arg18*)) which was considered as likely pathogenic (class IV variant; upper panel). Sanger-based segregation studies 
confirmed homozygosity for the same mutation in the index patient but showed heterozygosity only in the mother (black arrows in lower 
panel). (E) Further qPCR showed a deletion of MICU1 exon 2 in the patient and his father, whereas the adjacent exons 1 and 3 presented 
with two copies respectively. Quantitative PCR studies of MICU1 exons 1–3 in the mother revealed normal results
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RESULTS
Clinical presentation of the patients
The index patient was a girl, born as the first child of Turkish con-
sanguineous parents (Figure 1A) after an uneventful pregnancy (par-
ents had five prior miscarriages; Figure 1A). Whereas development of 
free walking was observed at age 18 months, speech development 
was delayed with her first words occurring at age 24 months and first 
sentences, at age 4 years. At this time, she showed normal tendon 
reflexes, normal muscle strength, moderate ataxia with frequent falls 
and reduced physical endurance. Chorea, dystonia, nystagmus or 
vitiligo were not recorded. She further showed extensive motor rest-
lessness with reduced attention and a sleep disorder with frequent 
awakenings at night. At the age of 5 years, at last follow-up, she had 
improved showing normal physical endurance, improved sleep pat-
terns, improved fine motor skills and markedly improved ataxic gait 
pattern. The parents, however, reported episodes of unsteady gait 
and reduced mobility which they attributed to lower limb pain. Slightly 
reduced global muscle strength, proximal muscular hypotonia, lum-
bosacral hyperlordosis and clinodactyly of the fifth fingers were noted 
(Figure 1B). Cognitive testing was in line with marked cognitive impair-
ment. Electroencephalography and brain MRI studies proved normal. 
Serum creatine kinase (CK) levels were repeatedly elevated ranging 
from 3000 to 5500 U/l. Genetic testing including karyotyping, CGH-
array, FMR1, DMPK, FXN and SMN1 as well as screening for Prader–
Willi syndrome gave normal results. The father was suffering from a 
progressive optic atrophy (visual acuity right =5%, left =20%), which 
could not be detected in our index patient. However, the reason for 
this clinical feature in the father has not been pursued.
The second patient is a previously health boy who at the age of 
22 months, in the course of an acute upper respiratory tract infec-
tion, suddenly developed acute ataxia which spontaneously regressed 
within 2 days. Laboratory studies revealed an elevated CK value of 
10,000 U/l which persisted during follow-up. At the age of 32 months, 
when he first presented to our hospital, he showed bilateral enlarge-
ment of the calf muscles, normal tendon reflexes, grossly normal mus-
cle strength with no Gower's sign and normal ability to climb stairs. 
He tended to walk on tiptoes, although no fixed pointed foot was 
present. At age 40 months, the parents reported he had an impaired 
sensitivity to pain and an increased tendency to fall, possibly related to 
a marked motor restlessness combined with persistent pointed foot. 
This restlessness combined with reduced attention was still noted 
at age 4 years. At the age of 5 years, at last follow-up, there was no 
Gower's sign but moderate proximal weakness with reduced exercise 
capacity attributed to exercise-related proximal muscle pain. Electro- 
and echocardiography proved normal.
Genetic testing
Whole genome sequencing of index patient 1 revealed a homozy-
gous G > A change within the coding region of the MICU1 gene 
on chromosome 10 (chr10: 74268012; c.553C>T; exon 6 of 12; 
Figure 1C). This nucleotide change results in a premature stop codon 
at amino acid position 185 p.(Arg185*), which has been described 
previously as being a pathogenic founder mutation in 13 patients 
from the Middle East [16]. This homozygous mutation is expected to 
lead to deficiency of the MICU1 protein, which was validated in the 
immortalised lymphoblastoid cells by immunoblotting (Figure 6B) 
and highly likely to be responsible for the disorder manifesting in 
the index patient. Segregation of the mutation in the family could be 
demonstrated (Figure 1C).
In patient 2, next generation sequencing (NGS)-based testing of 
myopathy genes using an Illumina enrichment kit revealed homozy-
gosity for a sequence variant in exon 2 of the MICU1 gene (chr10: 
74268012; c.52C>T, p.(Arg18*)) which was considered as likely patho-
genic (class IV variant) (Figure 1D). No further pathogenic sequence 
variants were detected in the regions of interest. The applied NGS-
based approach did not allow the distinction between homozygosity 
of the sequence variant, compound heterozygosity for the variant 
and a deletion overlapping the region of interest, or a uniparental 
isodisomy of chromosome 10. However, uniparental disomy of chro-
mosome 10 was excluded by using chromosome 10-specific microsat-
ellite markers. Using qPCR, we could show that the patient carries a 
heterozygous deletion comprising exon 2 of the MICU1 gene; exons 1 
and 3 of the MICU1 gene are not deleted (Figure 1E). The exact size 
of the deletion was not determined, and SNP array analysis failed to 
detect this relatively small deletion. Analysis of parental blood sam-
ples revealed that the mother is a heterozygous carrier of the c.52C>T 
(p.(Arg18*)) sequence variant, whereas the deletion is of paternal ori-
gin (Figure 1D,E). The patient is therefore compound heterozygous for 
two loss-of-function variants in the MICU1 gene.
Biopsy findings
Muscle histology including H&E, NADH, COX-SDH, ATPase and 
toluidine blue staining showed fibre calibre variation, occasionally 
internalised myonuclei, fibre-type grouping, groups of lesioned ba-
sophilic fibres, focally increased NADH-labelling consistent with 
irregular focal accumulation of mitochondria and/or sarcoplasmic 
reticulum in some muscle fibres, groups of COX-negative fibres and 
subsarcolemmal increase of enzyme histochemical activity (Figure 2). 
Gömöri trichrome-stained cryostat sections showed moderately in-
creased accumulation of subsarcolemmal fuchsinophilic material and 
minor lipid accumulation in a few muscle fibres by Oil Red O stain-
ing (Figure 2). There were no ragged-red fibres (Figure 2). In both 
patients, MICU1 mutations resulted in loss of protein expression in 
skeletal muscle (Figure S2).
Electron microscopic investigation of quadriceps muscle biopsies 
of the 40-month-old patient 1 and of the 32-month-old patient 2 re-
vealed severe mitochondrial pathology including enlarged mitochon-
dria showing abnormal cristae and accumulation of electron-dense 
material (most likely corresponding to protein aggregates) within 
the mitochondrial matrix (Figure 3). In addition, inordinate glycogen 
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deposits at the I-bands of the sarcomere structures were found in 
patient 1 (Figure 3). Further pathomorphological findings included 
proliferated and de-organised ER–Golgi structures and the presence 
of vacuoles occasionally filled with glycogen deposits and/or other 
electron-dense material most likely corresponding to aggregated 
proteins (Figure 3). These vacuoles were frequently located adjacent 
to abnormally lobulated myonuclei (Figure 3).
CARS is a non-linear variant of Raman spectroscopy employed 
here to investigate the biochemical composition of muscle biopsies 
without any dyes, labels or prior assumptions. CARS microscopy 
performed on muscle biopsies derived from the two MICU1 and 
two IBM patients as well as three adult and three juvenile controls 
(histological examination did not reveal any signs of myopathic fea-
tures or neurogenic muscular atrophy) revealed increased signals for 
F I G U R E  2  Light microscopic findings 
in the MICU1 patient-derived muscle 
biopsies. (A) Haematoxylin & eosin (H&E) 
staining of quadriceps muscle biopsy 
of index patient 1 reveals grouping of 
lesional basophilic muscle fibres (black 
arrows). (B) Focally increased NADH-
labelling in a proportion of MICU1-
diseased muscle fibres consistent with 
the accumulation of mitochondria and/
or sarcoplasmic reticulum (black arrows). 
(C) Gömöri trichrome-stained cryostat 
sections showing moderate increased 
accumulation of subsarcolemmal 
fuchsinophilic material (black arrow). 
(D) Oil Red O-stained cryostat sections 
showing lipid accumulation in few muscle 
fibres (black arrow). (E) H&E staining of 
quadriceps muscle biopsy of index patient 
2 reveals grouping of lesioned basophilic 
muscle fibres (black arrows). (F) Increased 
subsarcolemmal NADH-labelling in a 
proportion of muscle fibres (black arrows). 
(G) Gömöri trichrome-stained cryostat 
sections showing moderate increased 
accumulations of subsarcolemmal 
fuchsinophilic material (black arrow). 
(H) Oil Red O-stained cryostat sections 
showing lipid accumulation in few muscle 
fibres (black arrow). (I) COX-SDH staining 
revealed groups of COX-negative but 
SDH-positive (blue) fibres indicative 
for mitochondrial dysfunction (black 
arrows). (J) ATPase (pH: 4.2) staining 
revealed fibre-type grouping indicative 
for de-innervation processes (black 
arrows). (K) Toluidine blue staining 
of semi-thin sections shows calibre 
variations, subsarcolemmal increased 
staining corresponding to osmiophilic 
structures shown by EM (in Figure 3) 
and an internalised myonucleus (white 
arrow)
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the wave numbers 2930 cm−1, 2885 cm−1 and 2840 cm−1 in fibres 
of small calibre with particularly pronounced spot patterns in the 
MICU1 patient samples (Figure 4). These cells commonly show an 
increased organisation of lipid structures at 2885 cm−1 but not at 
2840 cm−1 (Figure 4). Given that mitochondria (in association with 
the SR/ER) are also involved in lipid synthesis [17], distribution pat-
terns of lipids in MICU1-mutant muscle fibres were further exam-
ined. Applying unmixing, increases in abundance of spectra with 
F I G U R E  3  Electron microscopic findings in the MICU1 patient-derived muscle biopsies. A-E: patient 1 and F-I: patient 2. (A) 
Subsarcolemmal swollen mitochondrion with disintegrated cristae and deposits of myelin-like material in degenerating mitochondria 
(black arrows). (B) Degenerating mitochondria surrounded by glycogen deposits and occasionally filled with electron-dense material (black 
arrows) and vacuoles filled with glycogen. Insets show further mitochondria adjacent to glycogen accumulations with prominent inclusion 
of myelin-like material corresponding to aggregated protein. (C) Degenerating mitochondrion adjacent to glycogen accumulations with 
inclusions of myelin-like material (black arrow) and intramyofibrillar glycogen deposits as well as proliferated cisternae of the sarcoplasmic 
reticulum (white arrows). (D) Subsarcolemmal accumulation of vesicular structures presumably corresponding to disintegrated ER/SR–Golgi 
structures. (E) Abnormally lobulated (black arrow) and fragmented (white arrow) myonucleus with adjacent vacuoles prominently filled 
with electron-dense material. (F) Subsarcolemmally enlarged mitochondria showing abnormal cristae. (G) Subsarcolemmal accumulation of 
myelin-like, electron-dense material adjacent to normal and enlarged mitochondria. (H) Subsarcolemmal accumulation of proliferated ER/
SR occasionally filled with myelin-like, electron-dense material (black arrows). (I) Accumulation of intermyofibrillar mitochondria adjacent to 
a non-subsarcolemmal myonucleus and associated with membranous structures in the cytoplasm suggestive of abnormal mitophagy (black 
arrows) and with proliferated vesicular structures presumably corresponding to Golgi vesicles (white arrow)
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high lipid but low protein content (represented through respective 
peaks) could be observed in muscle fibres of the two MICU1 patients 
(Figure 4). In addition, sarcolemmal enrichment of lipids with focal 
clustering indicative for aggregate formation could be observed by 
unmixing in patient-derived muscle biopsy specimen compared to 
control samples (Figure 4, Figure S1).
The evaluation of the unmixing enables us to compare differ-
ent parts of the fibre. Here, we compare the resulting spectra of 
the interior and the border of the fibre (Figure 4B, Figure S1). The 
spectra of the interior of control (endmember 1) and disease control 
(endmember 2) are quite similar in terms of peak position and ratio, 
and both are distinctively different from the one of MICU1 patients 
(endmember 4). The spectra for the borders support this, but for 
control (endmember 3 + 4) and MICU1 patients (endmember 2 + 5), 
there are now two spectra describing the border instead of just one. 
In contrast, there is just one for disease control (endmember 3). The 
spectral comparison suggests a similarity of biochemical composi-
tion in control and disease control, while the composition of muscle 
fibres of MICU1 patients is different, both inside the fibre and at its 
border.
Furthermore, CARS microscopy revealed the presence of areas 
with low signal intensity, sized between 0.5 and 1.5 µm (Figure 4). 
Those areas, which most likely represent (autophagic) vacuoles, 
show considerably lower peaks for all three wave numbers men-
tioned above, thus suggesting that those are not densely packed 
with aggregates of lipids or proteins. However, the disease controls 
also present with vacuoles, but with diameters ranging from 0.5 to 
20 µm. Furthermore, rimmed vacuoles were found in one disease 
control and filled vacuoles in the two disease controls (black arrows 
in Figure S1).
Moreover, degenerating muscle fibres presented with granu-
lar appearance in CARS microscopy defined by a dominant peak 
F I G U R E  4  CARS microscopic findings in the patient-derived muscle biopsies. (A) CARS and SHG contrast images of MICU1 patient and 
control muscle biopsies. The MICU1 patient-derived biopsies show clusters of muscle fibres with particularly pronounced spot patterns 
(white frames) not identified as such in the control and disease control muscles. Cells within these cluster present with increased protein 
(2930 cm−1 (ѵs(=CH3)) and lipid (2889 cm
−1 (ѵas(=CH2), 2840 cm
−1 (ѵs(=CH2)), as well as SHG signals. Scale bars 60 µm. (B) Round degenerating 
muscle fibres (black arrows) and fibres with reduced eosin staining (white arrow) were detected by H&E staining. In the superimposed CARS/
SHG images (scale bar 200 µm), round muscle fibres of similar structure were also detectable, sometimes as groups or clusters (uppermost 
arrow). These cells have an internal granular structure (scale bar 5 µm) and granules have a higher intensity at 2847 cm−1 than at 2889 cm−1 
indicating a lower lipid order (1). Besides, there are also elongated accumulations with a higher lipid order (2). Both structures show 
comparable protein signals at 2930 cm−1. Outside of these structures, the intensity of the three peaks is distinctively lower (3). The round 
muscle fibres are surrounded by SHG signals, maybe hinting to collagen or collagen-like structures. (C) Image of muscle fibre of a MICU1 
patient with autophagic vacuoles taken at 2885 cm−1 (lipid spectra). Spectra are shown from different locations: low intensities of protein 
and lipids are measured within the vacuoles (1). Two typical spectra recorded around the vacuoles are also presented, which mostly differ 
in intensity (2, 3). Scale bar 2.5 µm. (D) In the superimposed CARS/SHG images (scale bar 200 µm), round muscle fibres of similar structure 
were also detectable; sometimes as groups or clusters (uppermost arrow). These cells have an internal granular structure (scale bar 5 µm) 
and granules have a higher intensity at 2847 cm−1 than at 2889 cm−1 indicating a lower lipid order (1). Besides, there are also elongated 
accumulates with a higher lipid order (2). Both structures show comparable protein signals at 2930 cm−1. Outside of these structures, the 
intensity of the three peaks is distinctively lower (3). The round muscle fibres are surrounded by SHG signals, maybe hinting to collagen 
or collagen-like structures. (E) Comparison of the average muscle fibre calibres in the comparison of the controls with MICU1 patients. 
Statistical details are given in supplemental document 1. Star: difference to all controls is of high statistical significance
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a wave number 2840 cm−1 suggesting that lipid organisation is 
lower than observed in the above mentioned small-calibre fibres 
(Figure 4B). In addition, degenerating fibres are characterised by 
a SHG-signal suggestive for the presence of structured protein 
aggregates, a hallmark of cell degeneration [18,19]. To quantify 
changes in muscle fibre calibres, the diameter of muscle cells were 
calculated resulting in an averaged fibre diameter of 54.48 µm 
± 14.67 µm in adult controls, 40.29 µm ±8.54 µm in juvenile 
controls, 64.47 µm ±24.94 µm in disease controls and 23.01 µm 
± 6.83 µm in MICU1 patients (Figure 4) thus indicating muscle fibre 
atrophy in MICU1 patients as previously described by Logan and 
co-workers [5]. However, quantification of muscle fibres per area 
(mm2) revealed an average of 289 fibres in controls and 1534 fi-
bres in MICU1 patients (data not shown; not performed for disease 
controls).
Immunofluorescence-based analysis of patient-derived biopsies 
revealed reduced subsarcolemmal immunoreactivity of β-Spectrin in 
approximately 20% of MICU1-mutant muscle fibres of both patients 
(Figure 5A). The decreased sarcolemmal distribution of β-Spectrin in 
muscle fibres of MICU1 patients correlated with decreased protein 
abundance in whole muscle protein extracts analysed by immuno-
blot studies. Moreover, immunoblotting studies revealed decreased 
abundances of further costameric proteins including Dystrophin, 
β-Dystroglycan and Desmin. In contrast, α-, β- and γ-Sarcoglycan, 
Myotilin and Tubulin revealed normal results (Figure 5B).
Lymphoblastoid patient cells lack MICU1 and display 
dysregulation of mitochondrial Ca2+ uptake
Lymphoblastoid cells derived from the homozygous patient 1 
(red), healthy sibling (black) and heterozygous father (grey) were 
permeabilised in suspension and were used for fluorometric 
measurements of mitochondrial Ca2+ uptake (Figure 6A). Upon 
addition of a Ca2+ bolus that increased [Ca2+]c to ~1.5 µM, only 
the homozygous patient cell mitochondria displayed Ca2+ clear-
ance (left panel). By contrast, when [Ca2+]c was elevated above 
10 µM, the homozygous patient cell mitochondria showed lesser 
Ca2+ uptake than mitochondria of either the healthy sibling or het-
erozygous father (middle panel). Quantitative analysis of the Ca2+ 
clearance rates obtained with various Ca2+ boluses, a dose–re-
sponse plot was compiled that revealed suppressed Ca2+ depend-
ence of the mitochondrial Ca2+ uptake in the patient cells (right 
panel). Mitochondrial Ca2+ uptake by the patient cells (patient 1) 
F I G U R E  5  Protein studies on 
MICU1 patient-derived muscle biopsy 
specimen. (A) Immunofluorescence 
studies on cryopreserved muscle 
sections reveal reduced subsarcolemmal 
immunoreactivity of β-Spectrin (white 
arrows) in the quadriceps biopsy of both 
MICU1 patients compared to control 
muscles. (B) Immunoblot studies on 
whole muscle protein extracts reveal 
reduced level of β-Spectrin, Dystrophin, 
β-Dystroglycan and Desmin while level 
of α-, β- and γ-Sarcoglycan, Tubulin 
and Myotilin remain unchanged in the 
muscle of both patients compared to 
controls
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phenocopied the pattern previously observed with other MICU1-
deficient cells [2,6]. Lysates prepared from the cells were used for 
immunoblotting that showed loss of the MICU1 band in the ho-
mozygous patient (Figure 6B). Notably, the MICU1 bands as well 
as the mitochondrial Ca2+ uptake phenotypes were similar in the 
healthy sibling (control) and the heterozygous father (Figure 6AB). 
Immunoblot for EMRE that is required for the assembly of the MCU 
pore also showed a decrease in the homozygous patient, replicat-
ing a likely compensatory decrease in the uniporter abundance, 
which has been documented previously in cell lines [7,11,20] but 
not in patients [9]. This result has indicated that loss of MICU1 can 
initiate changes in the abundance of other proteins which are not 
directly targeted by the genetic impairment.
MICU1 mutations alter protein compositions in 
lymphoblastoid cells
Proteomic profiling utilising lymphoblastoid cells derived from pa-
tient 1 and the healthy sibling were carried out and allowed the 
F I G U R E  6  Ca2+ dependence of 
mitochondrial Ca2+ uptake and MICU1 
abundance in lymphoblastic cells of the 
patient and healthy and heterozygous 
family members. (A) Mean [Ca2+]c 
time courses measured using fura2FA 
(upper left panel) and fura2FFFA 
(upper right panel) in suspensions of 
permeabilised lymphoblastic cells show 
the mitochondrial clearance of a 3 µM 
or 30 µM CaCl2 bolus (left and right 
panel respectively). Thapsigargin (2 µM) 
and CGP-37157 (20 µM) were included 
in the buffer to prevent endoplasmic 
reticulum Ca2+ uptake and mitochondrial 
Ca2+ extrusion respectively. Means 
were calculated for three independent 
experiments that included 2–3 
measurements for each cell type. Lower 
panel: [Ca2+]c dose response of the initial 
mitochondrial uptake rates for different 
Ca2+ boluses recorded as shown in the 
upper left and right panels. The CaCl2 
doses added were (in µM) 3, 7, 15 and 30. 
Each symbol represent a measurement 
of one of the three separate experiments 
marked by circle, square and triangle 
symbols respectively. (B) Representative 
immunoblots showing the abundance of 
MICU1, EMRE and Heat Shock Protein 70 
(HSP70) proteins from the cell suspension 
samples harvested in the end of the 
fluorometric measurements shown in 
A. HSP70 was used as a mitochondrial 
loading control. Images are representative 
for three different experiments
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quantification of 2703 proteins, of which 800 presented with at least 
two unique peptides and a p-ANOVA <0.05 (Figure 7A). The proteomic 
response to the novel MICU1 mutation revealed increased abundance 
of 19, and decreased abundance of 20 proteins (Figure 7B,C). An over-
view of all affected proteins along with their subcellular localisations 
and functions is also provided in Figure 7. The proteomic signature 
of lymphoblastoid cells derived from our MICU1 patient 1 revealed 
altered abundance of five proteins localising to mitochondria includ-
ing interferon-induced protein with tetratricopeptide repeats 2 (IFIT2), 
caspase-1 (CASP1), protein-glutamine gamma-glutamyltransferase 2 
(TGM2), succinate-semialdehyde dehydrogenase (SSDH) and bifunc-
tional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 
(MTDC) (Figure 7). Whereas five additional affected proteins (not 
primarily localised to mitochondria) play known roles in the modula-
tion of mitochondrial morphology and function. These proteins in-
clude Syntaxin-5 (STX5), Spectrins (SPTAN1 and SPTBN1), MTDC 
and Vimentin (VIM). Moreover, six affected proteins act in a Ca2+-
dependent manner or are involved in Ca2+ signalling pathways includ-
ing calcium/calmodulin-dependent protein kinase type IV (CAMK4), 
vacuolar protein sorting-associated protein 37B (VPS37B), Drebrin 
(DBN1), Vimentin (VIM), Coactosin-like protein (COTL1), Endoplasmin 
(HSP90B1/ GRP94). The proteomic data have been deposited to the 
ProteomeXchange Consortium via the PRIDE [21] partner repository 
with the data set identifier PXD008867. Pathogenic mutations in 
genes corresponding to the affected proteins have been excluded by 
our sequencing data.
F I G U R E  7  Unbiased proteomic 
profiling of lymphoblastoid cells derived 
from MICU1 patient 1. (A) Applied 
proteomic workflow. (B) Volcano plot 
of obtained proteomic results (red dots 
represent proteins decreased and green 
dots proteins increased in abundance. 
(C) Categorisation of proteomic findings 
according to the function of the proteins 
affected in abundance upon the presence 
of the homozygous p.(Arg185*) mutation. 
(D) Subcellular localisations of the proteins 
affected in abundance upon the presence 
of the homozygous p.(Arg185*) mutation 
(red-labelled proteins are decreased and 
green-labelled proteins are increased in 
abundance)
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Immunostaining studies allow recapitulation of 
proteomic findings and provide further evidence 
for associated pathophysiologies in MICU1 patient-
derived muscle
Proteomic profiling on lymphoblastoid cells revealed the altered 
abundance of 39 proteins (see above). To further confirm this finding 
and demonstrate a similar pathobiochemical impact of MICU1 loss 
in muscle cells, immunostaining studies were carried out for paradig-
matic proteins. These studies confirmed an increase of Syntaxin-5 
(STX5) and Endoplasmin (GRP94), two proteins localising to the ER–
Golgi network, also in muscle cells. To further study the potential 
proliferation of ER–Golgi structures indicated by the results of our 
ultrastructural investigation, immunostaining for POC1A, a protein 
resident to this functional continuum, was performed showing an 
increased immunoreactivity in a proportion of MICU1-mutant mus-
cle cells (Figure S2). Based on this finding, we additionally studied 
the level of Calreticulin (CALR) and BiP, two Ca2+-binding chaper-
ones promoting protein quality control in the ER, along with Seipin 
(BSCL2), a protein mediating the formation and/or stabilisation of 
ER-lipid droplets and microtubule-associated proteins 1A/1B light 
chain 3B (LC-3) as well as lysosome-associated membrane glycopro-
tein 1 (LAMP1), two known protein aggregation markers. Compared 
to control muscle cells, focal increase was detected for these pro-
teins in MICU1-mutant muscle cells (Figure S2). Given that caspase-1 
(CASP1), acting as promotor of apoptosis in concert with cytochrome 
C (CytC), was identified with increased abundance in MICU1 patient-
derived lymphoblastoid cells, CASP1 and CytC level were studied 
in patient-derived muscle. Both proteins showed a focal increase in 
muscle cells of MICU1 patients compared to controls cells (Figure 
S2). Prompted by the results of our immunoblotting studies suggest-
ing a dysregulation of proteins involved in anchoring of the actin 
cytoskeleton to subcellular structures, additional immunostaining 
studies were carried out for Actinin-3 (ACTN3) and Integrin beta-4 
(ITGB4): both proteins showed an irregular sarcoplasmic increase in 
MICU1 patient-derived muscles (Figure S2).
DISCUSSION
MICU1 deficiency-associated phenotypes
Loss-of-function point mutations have been identified in MICU1 as 
the cause of a rare neuromuscular and neurodevelopmental disease 
in children [13]. So far, the clinical spectrum of MICU1 patients in-
cluded progressive proximal muscular dystrophy, elevated CK levels, 
generalised muscle weakness, positive Gower's manoeuvre, mild in-
tellectual disability or learning difficulties and variable features such 
as episodic ataxia, skin involvement, ptosis, hypometropia, pendular 
nystagmus, bilateral optic atrophy, microcephaly and peripheral ax-
onal neuropathy as well as elevated transaminase enzymes [5,9,16]. 
In addition, two cousins with a homozygous deletion involving exon 
1 (chr 10: 74,385,085–74,387,860, size: 2,775 nucleotide pairs) of 
MICU1 were described: one case presented with fatigue and leth-
argy associated with mild hypotonia, and global muscle weakness 
among other symptoms such as episodes of accompanied viral infec-
tions but normal psychomotor development. Remarkably, the other 
case carrying the same homozygous deletion presented with a more 
pronounced phenotype characterised by additional migraines, pen-
dular nystagmus, cataracts and mild learning difficulties [22]. Muscle 
biopsy studies commonly revealed rare atrophic fibres and increased 
internal nuclei. The variable clinical presentation resulting from 
MICU1 deficiency in this family underlines the broad clinical spec-
trum of the disease and shows that a clear genotype–phenotype 
correlation did not emerge. Further ‘larger’ genetic rearrangements 
associated with the clinical manifestation of a MICU1 phenotype in-
clude a heterozygous intragenic duplication of exons 9 and 10 [16] 
and a homozygous deletion of exon 1 [22].
Here, we describe two new MICU1 patients, one carrying the 
recently described homozygous Middle Eastern founder mutation 
(chr10: 74268012 G > A; c.553C>T; p.(Arg185*); minor allele fre-
quency of 1:60,000 in the ExAC database, but in ~1:500 individ-
ual in the Middle East [16]) and the other compound heterozygous 
nonsense p.(Arg18*) mutation combined with an intragenic deletion 
affecting exon 2 (the two latter mutations have not been observed 
previously). Both patients presented with developmental delay, 
highly elevated CK level, and histological and ultrastructural changes 
in muscle biopsy specimens compatible with a myopathy associated 
with MICU1 deficiency. Moreover, the phenotype of both patients 
was dominated by the presence of ataxia suggesting that this clinical 
feature is one of the symptoms more frequently present in this mul-
tisystemic disease. Notably, further clinical findings in our patients 
included clinodactyly, hyperactivity and insomnia as well as impaired 
cognitive pain perception (due to restlessness and attention prob-
lems) thus expanding the currently known phenotypic spectrum of 
MICU1 deficiency.
Microscopic biopsy findings in muscle biopsy 
specimen of MICU1 patients in correlation with 
proteomic signature of lymphoblastoid cells
Microscopic studies of the muscle biopsies, including light, electron 
and CARS microscopic examinations, revealed the loss of MICU1 ex-
pression based on the respective molecular genetic defects leading 
to atrophy affecting slow and fast muscle fibres. According to the 
subcellular localisation and function of MICU1, severe mitochondrial 
perturbations in the muscle fibres were indicated by histological 
findings and moreover clearly identified by electron microscopy. This 
observation accords with the previously described mitochondrial 
fragmentation in fibroblasts upon deficiency of functional MICU1 
and perturbed Ca2+ homeostasis [9] as also exemplified in our in 
vitro model (Figure 6). Further ultrastructural changes include disin-
tegration of ER–Golgi structures and the presence of vacuoles filled 
with protein aggregates expanding the currently known spectrum 
of ultrastructural abnormalities associated with MICU1 deficiency. 
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Proteomic profiling results obtained from lymphoblastoid cells pre-
sented in this study revealed altered abundances of proteins be-
longing to the functional ER–Golgi network. Interestingly, impaired 
function of this network (also mirrored in disintegrated morphology) 
has been often linked to impaired protein processing and build-up of 
(autophagic) vacuoles in a variety of neurological diseases.
CARS microscopy can provide spatially resolved information 
about the biochemical composition of the sample, and by such, also 
resolve morphological structures or respective alterations. Here, 
our CARS microscopic studies revealed an increased organisation 
of lipid structures in a proportion of small-calibre muscle fibres in 
both MICU1 patients. Given that lipids are synthesised at distinct 
parts of the cell including the ER–Golgi network and mitochondria 
[23], and these organelles in turn form a functional continuum due to 
the formation of mitochondria-associated ER membranes (MAMs), 
also involved in the transport of Ca2+ [24-26] and based on lipid 
synthesis [17], an influence of MICU1 deficiency on proper cellular 
lipid homeostasis can be hypothesised. In this context, immunoblot 
studies of Seipin (BSCL2), a protein mediating the formation and/
or stabilisation of endoplasmic reticulum-lipid droplets, revealed 
increased abundance in MICU1 patient-derived muscles (Figure S2). 
In addition, the absence of a respective lipid peak in degenerating 
muscle fibres suggests that the increased appearance of organised 
lipid structures does not represent a pathophysiological correlate of 
initiated apoptosis. In contrast, muscle cells were characterised by 
the presence of protein accumulations identified by CARS micros-
copy. Given that lipids are the building blocks of cellular membranes 
such as the muscle cell plasma membrane, the CK-increase observed 
in MICU1 patients might also be caused by increased membrane per-
meability as an effect of impaired lipid homeostasis. However, addi-
tional lipidomic investigations in combination with functional studies 
of membrane permeability on (cultured) MICU1-deficient muscle 
cells would be needed to confirm this assumption. In addition, our 
CARS microscopic findings confirmed the presence of vacuoles in 
MICU1-deficient muscle fibres. However, the considerable reduced 
peaks of the three measured wave numbers suggested that neither 
lipids nor proteins are enriched within these vacuoles appearing as 
areas with low signal intensity in the contrast representation of the 
CARS measurements. Electron microscopic studies (see above) re-
vealed the presence of small vacuoles which are only occasionally 
filled with myelin-like (electron-dense) material most likely corre-
sponding to protein and/or lipid aggregates.
Mitochondrial and cytoskeletal pathology caused by 
deficiency of functional MICU1
The dysregulation of 16 proteins (40% of all vulnerable proteins) can 
be directly linked to altered mitochondrial Ca2+ handling and thus 
MICU1 dysfunction resulting in ultrastructural mitochondrial pathol-
ogy (swollen mitochondria, cristae-disorganisation and build-up of 
aggregates within the mitochondrial matrix; Figure 3). This biochem-
ical finding accords with the proven perturbed Ca2+ homeostasis 
in the patient-derived lymphoblastoid cells (Figure 6) and provides 
novel insights into the biochemical consequences. Importantly, per-
turbed Ca2+ homeostasis has already been described in fibroblasts 
derived from MICU1 patients.[9]
A growing body of evidence suggests that mitochondrial morphol-
ogy and function are modulated by the cytoskeleton via mostly un-
characterised pathways [27] and our proteomic findings hint towards 
a vulnerability of cytoskeleton upon loss of MICU1 by altered abun-
dance of SPTBN1, SPTAN1, DBN1, VIM and COTL1. Vulnerability of 
Spectrin could also be observed by immunological investigations in the 
muscle biopsies of our two MICU1 patients (Figure 5). Interestingly, 
Ca2+ is known to modulate the stabilisation of Actin–Spectrin com-
plexes [28] and altered mitochondria with impaired capacity to buffer 
receptor-gated Ca2+ fluxes have already been linked to promotion of 
Ca2+-activated proteases and subsequent degradation of the Spectrin 
meshwork [29], thus confirming a tight connection between mito-
chondrial and Spectrin homeostasis. In addition, DBN1, VIM and 
COTL1 are also proteins that bind to actin in a Ca2+-dependent manner 
[30-32], which functioning in concert with Spectrins, modulate actin 
dynamics. Of note, immunoblotting studies on patient-derived muscle 
protein extracts revealed decreased abundance of further costameric 
proteins including Dystrophin, β-Dystroglycan and Desmin supporting 
the concept of a perturbed anchoring of the actin cytoskeleton to the 
sarcolemma as part of MICU1-associated pathophysiology. In addi-
tion, perturbed anchoring of the Actin cytoskeleton to organelles and/
or the sarcolemma is suggested by the irregular sarcoplasmic increase 
of ITGB4 and ACTN3, two proteins involved in anchoring of Actin 
to a variety of intracellular structures, in MICU1 patients (Figure S2). 
However, additional functional und structural studies on single iso-
lated fibres would be needed to elucidate this pathobiochemical inter-
play more precisely. Given that impairment of cytoskeletal dynamics 
and mitochondrial dysfunction are commonly observed in many neu-
rodegenerative and neuromuscular disorders [1,33-37], it seems to be 
plausible that vulnerability of regular cytoskeletal composition results 
from MICU1 deficiency-based mitochondrial dysfunction and signifi-
cantly contributes to the phenotypical manifestation of loss-of-func-
tion MICU1 mutations in different tissues. Remarkably, β-III-Spectrin 
spinocerebellar ataxia type 5 mutation reveals a dominant cytoskeletal 
mechanism that underlies dendritic arborisation [38].
ER–Golgi pathology and the presence of autophagic 
vacuoles caused by loss of functional MICU1
Altered abundance of ER–Golgi proteins might accord with mitochon-
drial vulnerability and could represent a secondary pathophysiologi-
cal mechanism: proteomic profiling revealed increased Syntaxin-5 
(SNX5), which belongs to the SNARE complex facilitating the trans-
port of cholesterol to mitochondria [39] (lipid accumulation has been 
identified in MICU1 patients based on our CARS microscopic stud-
ies), and SNX5 is also involved in vesicle tethering and fusion at the 
cis-Golgi membrane to maintain the stacked and inter-connected 
structure of the Golgi apparatus. Interestingly, our immunological 
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studies on muscle biopsy specimen confirmed an increase of SNX5, 
as well as an increase of POC1A, an ER–Golgi-resident protein, in 
a proportion of MICU1-mutant muscle cells (Figure S2). In addition, 
electron microscopy showed a build-up of proliferated and de-or-
ganised ER–Golgi structures (Figure 3). A potential impact of altered 
Golgi architecture—as observed in the muscle biopsies—on regular 
vesicular transport can also be deduced from our proteomic findings 
through the altered abundance of vesicular trafficking regulators 
such as VPS37B and AP-3 complex subunit mu-1 (AP3 M1): VSP37B 
is a Ca2+-dependent binding protein of the endosomal sorting com-
plexes required for transport (ESCRT) required for vesicular traffick-
ing processes [40]. AP3 M1 is part of the AP-3 adaptor complex, 
which associates with the Golgi, facilitates the budding from the 
Golgi and may be directly involved in trafficking to the endosomal or 
lysosomal system [41]. The expression of the AP-3 complex is essen-
tial for the biogenesis of acidic Ca2+ and polyphosphate organelles 
(so called acidocalcisomes) including lysosomes [42] with various 
functions including autophagy [43]. Interestingly, the results of our 
ultrastructural investigations revealed the presence of autophagic 
vacuoles (occasionally filled with electron-dense material) in mus-
cle fibres of our patients (Figure 3). Thus, one might speculate that 
increased expression of AP3 M1 and other proteins involved in pro-
teolysis such as Serpin B10 (SBP10; increased in the patient-derived 
lymphoblastoid cells) accords with the presence of vacuoles in the 
muscle biopsies of MICU1 patients. This assumption is supported by 
the results of our immunostaining studies on patient-derived muscle 
biopsies showing an increase of LAMP1 and LC-3, two protein ag-
gregation markers involved in modulation of autophagy (Figure S2). 
Along this line, data of our proteomic profiling on lymphoblastoid 
cells revealed increased abundance of FAM129A (protein Niban). 
Niban has recently been linked to autophagy-induction activated 
by perturbed Ca2+ homeostasis and ER stress [44]. Potential conse-
quences of MICU1 mutations on the intracellular Ca2+ dynamics in 
ER–mitochondria crosstalk [45] are further supported by the identi-
fied increased abundance of Endoplasmin, a Ca2+-buffering chaper-
one of the ER [46], in both MICU1 patient-derived lymphoblastoid 
cells and muscle. Also, the increase of BiP and Calreticulin in patient-
derived muscle cells accords with this concept.
Activation of pro-apoptotic and pro-survival 
mechanisms caused by MICU1 mutation
Apart from a role of AP-3 in Golgi maintenance and protein clear-
ance, a correlation between AP-3-function and the interferon 
signalling pathway has been described [47], and dysregulation of in-
terferon proteins (along with caspases and B-cell lymphoma-protein 
2 (BCL2); Tab. 1) as observed in our proteomic data is known to lead 
to cellular apoptosis by inducing the expression of several apoptotic 
regulators (including caspases and BCL2) via a mitochondrial path-
way [48]. Along this line, increased abundance of SBP10 and TNF 
receptor-associated factor 1 (TRAF1) accords with potential induc-
tion of apoptosis [49,50]. In this context, it is important to note that a 
recent study demonstrated the control of TRAF1 along with CAMK4 
(also increased in our in vitro system) on the molecular genetic level 
upon muscle loading highlighting their involvement in muscle fibre 
hypertrophy and thus muscle cell survival [51]. Induction of apop-
totic processes in MICU1 patient-derived muscle cells is indicated by 
the combined increase of CASP1 and CytC (Figure S2), in turn sup-
porting the relevance of proteomic findings obtained in the lympho-
blastoid cells. However, an increased abundance of proteins with 
neuroprotective properties have also been identified, in agreement 
with the concept of activation of pro-survival mechanisms: Uridine 
5'-monophosphate synthase (UMPS) is involved in synthesising UMP 
from orotate and deficiency of UMPS has been linked to hereditary 
orotic aciduria, which is associated with some degree of physical 
and mental retardation [52]. Succinate-semialdehyde dehydroge-
nase (ALDH5A1) catalyses one step in the degradation of the inhibi-
tory neurotransmitter gamma-aminobutyric acid [53]. Additionally, 
MTHFD2 (human MTDC), also elevated in the lymphoblastoid cells 
of our patient, modulates neuronal development via mitochondrial 
formate production [54,55] and thus most likely antagonises mito-
chondrial vulnerability in tissue upon loss of functional MICU1.
Biochemical and clinical synopsis
We hypothesise that impaired Ca2+ dynamics and concomitant in-
crease in lipid clustering, as well as dysregulation of proteins involved 
in metabolic processes (Figure 7) do reversibly and transiently affect 
cellular metabolic processes (also influencing further cellular func-
tion such as protein trafficking). This might accord with the observa-
tion of fluctuating symptoms in MICU1 patients such as episodes of 
pain-related unsteady gait in patient 1 as well as transient infection-
induced ataxia and exercise-related episodic pain in patient 2.
In summary, we describe novel, loss-of-function mutations of 
MICU1 in two patients expanding the mutational and clinical spec-
trum of the disease. Our combined ultramorphological, functional, 
proteomic and microscopic studies of human samples provide 
new insights into the molecular aetiology of the disease and point 
out that perturbed Ca2+ homeostasis caused by loss of functional 
MICU1 might affect cellular functions and organelle compositions 
beyond mitochondrial maintenance including lipid homeostasis, 
vulnerability of cytoskeletal components such as Spectrin as well 
as of the ER–Golgi network impacting on proper protein clearance. 
However, biochemical studies on cells and/or muscle biopsies of fur-
ther MICU1 patients confirming the data described here are needed 
to finally declare our findings as pathophysiological cascades result-
ing from the loss of functional MICU1.
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